A Double-Blind, Randomised, Placebo-Controlled Study to Evaluate the Efficacy of Cat-PAD in Cat Allergic Subjects Following Challenge to Cat Allergen in an Environmental Exposure Chamber.
Phase of Trial: Phase II
Latest Information Update: 20 Nov 2009
At a glance
- Drugs Cat SPIRE (Primary)
- Indications Hypersensitivity; Rhinoconjunctivitis
- Focus Therapeutic Use
- 20 Nov 2009 Actual number of patients changed from 120 to 121 according to Circassia media release.
- 20 Nov 2009 Circassia Announces Successful Results From Phase II Clinical Study of ToleroMune(R) Cat Allergy Therapy.
- 10 Jul 2009 Actual end date (May 2009) added as reported by ClinicalTrials.gov.